Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research on Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.
Location: Spain, Catalonia, Barcelona
Employees: 11-50
Total raised: $20.05M
Founded date: 2014
Investors 4
| Date | Name | Website |
| - | Alta Life ... | altals.com... |
| 05.11.2025 | Asabys Par... | asabys.com... |
| - | Healthequi... | healthequi... |
| - | Aurora Sci... | aurorascie... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.12.2020 | - | $13.9M | - |
| 06.09.2017 | Series A | $5.01M | Alta Life ... |
| 28.04.2016 | Seed | $1.14M | - |
Mentions in press and media 12
| Date | Title | Description |
| 16.05.2024 | Peptomyc has been granted 40.000 € within the ACTIVA startups | Read the full press release here: |
| 22.03.2024 | Peptomyc Appoints Selwyn Ho to its Board of Directors | Barcelona, Spain, March 21st, 2024 Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, ... |
| 26.02.2024 | Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. | OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble facto... |
| 14.02.2024 | Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial | Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine |
| 18.03.2021 | Green light by the AEMPS to start clinical trials with OMO-103 | http://www.peptomyc.com/green-light-by-the-aemps-to-start-clinical-trials-with-omo-103/ |
| 21.12.2020 | Peptomyc announces new equity financing round led by Aurora Science | Peptomyc, a biotech company specialized in the development of protein and peptide therapeutics for cancer treatment, has just announced the completion of an equity financing round of EUR 11.4 million. The company is focused on the developme... |
| 16.12.2020 | Peptomyc cierra una ronda de €11,4M liderada por AurorA Science. Acuden también Alta Life Sciences, HealthEquity, el CDTI y business angels | 16/12/2020 Nota de prensa PEPTOMYC CIERRA UNA RONDA DE €11,4M LIDERADA POR AUROA SCIENCE. ACUDEN TAMBIÉN ALTA LIFE SCIENCES, HEALTHEQUITY, EL CDTI Y BUSINESS ANGELS. Peptomyc S.L., empresa biotecnológica especializada en el desarrollo de... |
| 05.10.2018 | Innovations in the fields of energy, health and food: The winners of the EIT Awards 2018 | Yesterday evening, the European Institute of Innovation & Technology (EIT) rewarded Europe’s top entrepreneurs Simone Accornero (Italy), Ioannis Tamanas (Greece), Bieke Van Gorp (Belgium), Isabel Hoffmann (Canada) and Laura Soucek (Ital... |
| 07.09.2017 | Peptomyc cierra ronda de €4,2M liderada por Alta Life Sciences, acuden actuales Healthequity y BA | 07/09/2017 Nota de prensa PEPTOMYC CIERRA UNA RONDA DE €4,2 MILLONES LIDERADA POR ALTA LIFE SCIENCES, ACUDEN LOS ACCIONISTAS ACTUALES HEALTHEQUITY Y BUSINESS ANGELS. Peptomyc S.L., compañía biofarmacéutica con sede en Barcelona que desar... |
| 06.09.2017 | Peptomyc S.L. secures 4.2 million euros in Series A led by Alta Life Sciences | Peptomyc S.L., a Barcelona-based biotech company developing new peptide therapeutics for the treatment of cancer patients, announces the closure of a Series A financing of 4.2 million euros. The investment round was led by Alta Life Science... |
Show more